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sPurpose: The incidence of Candida bloodstream infections
(BSI) has increased over the past two decades. The rank order
of occurrence and the susceptibility to antifungals of the
various Candida species causing BSI are important factors
driving the establishment of empirical treatment protocols;
however, very limited multi-institutional data are available on
Candida bloodstream isolates in Korea. Materials and Methods:
We investigated the susceptibility to azole antifungals and
species distribution of 143 Candida bloodstream isolates
recovered from eight university hospitals over a six-month
period. Minimal inhibitory concentrations (MICs) of fluco-
nazole, itraconazole, and voriconazole for each isolate were
determined by the broth microdilution method of the Clinical
and Laboratory Standards Institute (CLSI). Results: The Can-
dida species recovered most frequently from the blood cultures
was C. albicans (49%), followed by C. parapsilosis (22%), C.
tropicalis (14%), and C. glabrata (11%). The MIC ranges for
the Candida isolates were 0.125 to 64 g/mL for fluconazole, μ
0.03 to 2 g/mL for itraconazole, and 0.03 to 1 μ g/mL for μ
voriconazole. Overall, resistance to fluconazole was found in
only 2% of the Candida isolates (3/143), while the dose-
dependent susceptibility was found in 6% (8/143). The resis-
tance and dose-dependent susceptibility of itraconazole were
found in 4% (6/143) and 14% (20/143) of the isolates,
respectively. All bloodstream isolates were susceptible to
voriconazole (MIC, 1 g/mL). μ Conclusion: Our findings
show that C. albicans is the most common cause of
Candida-related BSI, followed by C. parapsilosis, and that the
rates of resistance to azole antifungals are still low among
bloodstream isolates in Korea.
Key Words: Candida species, antifungal susceptibility, bloods-
tream infections, triazoles
INTRODUCTION
The incidence of Candida bloodstream infections
(BSI) has increased substantially over the past two
decades. Candida species are the fourth most
frequent source of BSI, accounting for 8-15% of all
cases of hospital-acquired sepsis in the USA.
1 In
Korea, the incidence of Candida-related BSI has
been reported to be about 0.012 per 100 admi-
ssions in two university hospitals.
2 The increased
incidence of Candida-related BSI is most likely
associated with the growing population of patients
undergoing chemotherapy, transplant surgery,
and intensive care support.
3,4 Candida- related BSI
have emerged as a major challenge for hospital
patients because they are associated with high
morbidity, prolonged hospital stays, high
attributable mortality (~40%), and substantial
health care costs.
1
The rank order of occurrence and antifungal
susceptibility of the various species of Candida
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that cause BSI are important for establishing
empirical treatment protocols.
5,6 There has been
increased concern regarding the possible changes
in species distributions and azole susceptibility of
Candida bloodstream isolates due to the widespread
use of fluconazole over the past decade.
4,5 In fact,
several surveillance programs have documented
variations in these parameters among institutions,
localities, and countries.
4,5,7-12 In Korea, a nationwide
antimicrobial resistance surveillance on clinically
relevant bacteria has been conducted since 1997.
13
However, a multi-institutional survey of Candida-
related BSI has not been performed in Korea, even
though fluconazole use has increased significantly
over the past ten years.
In this study, the distribution of Candida
bloodstream isolates in Korea was analyzed, and
the antifungal susceptibility of the isolates to
fluconazole, itraconazole, and voriconazole was
determined. This is the first nationwide sur-
veillance study of BSI-causing Candida isolates to
be conducted in Korea.
MATERIALS AND METHODS
Isolates
During a six-month period from November
2004 to April 2005, Candida bloodstream isolates
were prospectively collected at the eight uni-
versity hospitals in Korea: Chonnam National
University Hospital (Gwangju), Yonsei University
Medical Center (Seoul), Asan Medical Center
(Seoul), Inje University Sanggye Paik Hospital
(Seoul), Wonju Christian Hospital (Wonju), Ajou
University Hospital (Suwon), Chonbuk National
University Hospital (Jeonju), and Pusan National
University Hospital (Busan). All isolates were
recovered from blood cultures at each of the
participating institutions by using their routine
culture methods. For all 193 Candida bloodstream
isolates that were collected, both the species
identification and the antifungal susceptibility
testing were performed at the Chonnam National
University Hospital. Of these organisms, a total of
143 bloodstream isolates were included in the
study in order to analyze the species distribution
and for the antifungal susceptibility testing. These
organisms were recovered from 138 patients; with
five of the patients having two different Candida
species identified. Of the 138 patients, 40 (29%)
had two or more blood cultures that were positive
for the same Candida species, but only one Candida
species isolate (the first isolate) from each patient
was included. Species identification was based on
colony morphology by using CHROMagar Can-
dida (BBL, Becton Dickinson, Sparks, MD, USA) at
35 , microscopic morphology on cornmeal-
Tween 80 agar, and the use of a commercial
system (API 20C; bioMérieux, Marcy L’Etoile,
France, or the Vitek 2 system; Vitek 2 ID-YST,
bioMérieux).
Antifungal susceptibility testing
Susceptibility to antifungals was tested by a
broth microdilution assay according to the
methods of the Clinical and Laboratory Standards
Institute (CLSI, document M-27 A2),
14 using the
following drugs: fluconazole (Pfizer, Inc., New
York, NY, USA), itraconazole (Janssen Pharma-
ceutica, Beerse, Belgium), and voriconazole (Pfizer
Global Research & Development, Sandwich, UK).
The RPMI-1640 medium without bicarbonate was
prepared with L-glutamine and buffered at pH 7.0
with 0.165-M morpholinopropanesulfonic acid
(MOPS). Each yeast inoculum suspension was
prepared using a spectrophotometer in order to
obtain a final concentration of 0.5-2.5 × 10
3
cells/mL. The trays were incubated in air at 35 ,
and the minimal inhibitory concentration (MIC)
endpoints were read visually after 48 h. To elimi-
nate the effects of trailing growth, spectrophoto-
metric end points for fluconazole, itraconazole,
and voriconazole were also determined after 48 h.
Visual and spectrophotometric end points were
defined as the lowest drug concentrations that
resulted in a prominent decrease in growth and
a 50% reduction in optical density, respectively,
when compared to the data of the drug-free
growth control well.
14-16 Quality control was
performed by testing the Candida strains reco-
mmended by CLSI,
14 which were the C.
parapsilosis ATCC 22019 and the C. krusei ATCC
6258.
The interpretive susceptibility criteria used for
fluconazole and itraconazole were the same asAntifungal Resistance of Candida BSI Isolates
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those specified by the CLSI.
14 For fluconazole,
MICs 8 g/mL were considered susceptible, μ
while MICs between 16 and 32 g/mL were μ
considered susceptible dependent upon dose
(SDD), and MICs 64 g/mL were considered μ
resistant. Isolates of C. krusei are considered
resistant to fluconazole, irrespective of the MIC.
For itraconazole, MICs 0.125 g/mL were μ
considered susceptible, MICs between 0.25 and 0.5
g/mL were regarded as SDD, and MICs μ 1 μ
g/mL were considered resistant. For voriconazole,
the tentative interpretive breakpoints recently
established for its use with Candida species were
used (i.e., susceptible, 1 g/mL; SDD, 2 μ g/mL; μ
and resistant, 4 g/mL). μ
17
Statistical analysis
Comparisons of species distribution and MIC
distribution were determined by the chi-square test
for categorical variables and the Wilcoxon rank
sum test for ordinal variables. A p value < 0.05
indicated statistical significance.
RESULTS
Species distribution
The frequency of BSI due to various Candida
species in the eight different hospitals is shown in
Table 1. Among the 143 isolates collected from the
138 patients, 49% were C. albicans, 22% were C.
parapsilosis, 14% were C. tropicalis, 11% were C.
glabrata, 2% were C. guilliermondii, and 1% was C.
krusei. While the predominant species in all but
one hospital (hospital G) was the C. albicans, the
species distribution of the isolates varied among
the hospitals. For example, the frequency of BSI
due to C. albicans varied considerably, ranging
from 64% (hospital B) to 33% (hospital A) (p <
0.05). In general, however, C. parapsilosis was the
most common non-albicans species. In fact, it was
the most common isolate in one hospital (hospital
G) and the second most common isolate in six of
the eight hospitals. C. glabrata was the most
common cause (equal to C. albicans) of BSI in only
one hospital (hospital A, 33%), and C. tropicalis
was the third-or fourth-ranked species in most of
the hospitals.
Susceptibility to triazoles
The antifungal susceptibility to fluconazole,
itraconazole, and voriconazole was determined for
a total of 193 Candida bloodstream isolates from
138 patients. In 40 patients with serial blood-
stream isolates of the same Candida species, all
strains from the same patient had the same or
similar MICs of fluconazole, itraconazole and
voriconazole. The in vitro triazole susceptibility
results of the 143 isolates from 138 patients
(including 133 patients with one Candida species
isolate and five patients with two different
Candida species isolates) are shown in Table 2. The
fluconazole MICs for all of the isolates ranged
from 0.125 to 64 g/mL. The fluconazole MIC μ 90 of
the four most common species, C. albicans, C.
Table 1. Species Distribution of Candida Bloodstream Isolates in Each of the Eight Hospitals in Korea
Species
Isolates by hospital (n)
A B C D E F G H Total (%)
C. albicans 9 14 7 10 11 11 4 4 70 (49)
C. parapsilosis 4 4 5 6 3 3 5 2 32 (22)
C. tropicalis 4 2 3 5 3 2 1 0 20 (14)
C. glabrata 9 1 1 2 1 1 0 1 16 (11)
C. guilliermondii 0 1 0 1 0 1 0 0 3 (2)
C. krusei 1 0 1 0 0 0 0 0 2 (1)
Total 27 22 17 24 18 18 10 7 143 (100)Jin-Sol Lee, et al.
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parapsilosis, C. tropicalis, and C. glabrata, were 0.5,
2, 1, and 32 g/mL, respectively. All isolates of μ C.
albicans and C. tropicalis were susceptible to
fluconazole. Among the 32 C. parapsilosis isolates,
two were fluconazole SDD while the others were
susceptible. Of 16 C. glabrata isolates, 6% (1/16)
were fluconazole resistant, and 38% (6/16) were
SDD. Overall, resistance to fluconazole was found
in only 2% (3/143) of the Candida isolates (one C.
glabrata strain and two C. krusei strains), and
dose-dependent susceptibility was found in 6%
(8/143) of all the isolates.
The MICs of all bloodstream isolates ranged
from 0.03 to 2 g/mL for itraconazole and from μ
0.03 to 1 g/mL for voriconazole. The itraconazole μ
MIC90s for C. albicans, C. parapsilosis, C. tropicalis,
and C. glabrata were 0.06, 0.125, 0.25, and 2 μ
g/mL, respectively. Itraconazole resistance and
SDD were observed for 4% (6/143) and 14%
(20/143) of the Candida isolates, respectively. Of
16 C. glabrata isolates, 38% (6/16) of them were
itraconazole-resistant and 56% (9/16) were SDD.
All C. albicans isolates were susceptible to itraco-
nazole. Voriconazole was highly active (MIC90,
0.25 g/mL) against all of the μ Candida isolates
tested. The MIC50 and MIC90 of voriconazole
Table 2. Comparison of MICs of Three Antifungal Agents Against 143 Bloodstream Isolates of Candida
Candida species Antifungal agent
MIC ( g/mL) μ
Percent R
* Percent SDD
*
Range MIC50 MIC90
C. albicans (n = 70) Fluconazole 0.125 - 0.5 0.25 0.5 0 0
Itraconazole 0.03 - 0.06 0.03 0.06 0 0
Voriconazole 0.03 - 0.06 0.03 0.03 - -
C. parapsilosis (n = 32) Fluconazole 0.25 - 32 1 2 0 6
Itraconazole 0.03 - 0.5 0.06 0.125 0 6
Voriconazole 0.03 - 0.5 0.03 0.06 - -
C. tropicalis (n = 20) Fluconazole 0.125 - 1 0.25 1 0 0
Itraconazole 0.03 - 0.25 0.06 0.25 0 20
Voriconazole 0.03 - 0.25 0.03 0.06 - -
C. glabrata (n = 16) Fluconazole 4 - 64 8 32 6 38
Itraconazole 0.125 - 2 0.5 2 38 56
Voriconazole 0.06 - 1 0.25 0.5 - -
C. guilliermondii (n = 3) Fluconazole 1 - 8 4 ND 0 0
Itraconazole 0.25 - 0.5 0.5 ND 0 100
Voriconazole 0.125 0.125 ND - -
C. krusei (n = 2)
† Fluconazole 32 - 64 ND ND 100 0
Itraconazole 0.5 ND ND 0 100
Voriconazole 0.25 - 0.5 ND ND - -
Total (n = 143) Fluconazole
† 0.125 - 64 0.25 8 2 6
Itraconazole 0.03 - 2 0.03 0.5 4 14
Voriconazole 0.03 - 1 0.03 0.25 - -
*R and SDD, resistant and susceptible-dose dependent, by using the interpretive breakpoint criteria of the CLSI.
14
†Isolates of C. krusei are considered resistant to fluconazole, irrespective of the MIC.Antifungal Resistance of Candida BSI Isolates
Yonsei Med J Vol. 48, No. 5, 2007
against C. glabrata were 0.25 and 0.5 g/mL, μ
respectively. The voriconazole MICs of the two C.
krusei isolates were 0.25 and 0.5 g/mL. Based on μ
our putative breakpoints, all of the isolates were
susceptible to voriconazole (MIC 1 g/mL). μ
DISCUSSION
The treatment of Candida-related BSI was con-
siderably enhanced by the introduction of fluco-
nazole in 1990;
18 however, since the introduction
of azoles, an increase in the prevalence of C.
glabrata and C. krusei bloodstream isolates with
reduced susceptibilities to triazole antifungals has
been reported, and acquired azole resistance of C.
albicans isolates (e.g., in mucosal diseases in
acquired immunodeficiency syndrome) has be-
come a major concern.
19,20 In this study, the
species distribution and azole antifungal suscep-
tibility of Candida species isolates recovered from
patients with BSI at eight university hospitals in
Korea during a six-month period were evaluated.
Although the non-albicans Candida species repre-
sent more than half of all candidemic cases, this
study determined that C. albicans is the most
frequent etiologic agent of candidemia in Korea.
This finding, together with data from other
countries,
7-11,21,22 confirms that C. albicans is still a
leading cause of Candida-related BSI worldwide.
Nevertheless, the prevalence of C. albicans (49%)
in this study was significantly lower than that in
Canada (59%) (p < 0.05); however, it was similar to
the prevalence found in Latin America (47%).
21
Japan has the lowest reported frequency of C.
albicans (41%) among BSI isolates.
23
While C. glabrata is the second most common
Candida species associated with BSI in the United
States (18%) and Canada (20%),
21 the C. glabrata-
related candidemia represented only 11% of the
candidemic episodes in this study, which is
comparable to rates reported in Europe (13%) and
Latin America (8%).
21,24 In addition, the frequency
of isolation of intrinsically azole-resistant C. krusei
was low (1%) in our study. The higher frequency
of C. glabrata and C. krusei in the United States and
Canada may be explained in part by their
extensive use of relatively low doses of fluco-
nazole (< 400 mg/day).
5
In this study, C. parapsilosis was the most
common non-albicans species identified, which is
consistent with the data from Japan,
23 Canada,
and South America.
25 C. parapsilosis has become
increasingly important as a cause of catheter-
related BSI,
26,27 and its infections are often
associated with hyperalimentation due to breaches
in catheter care or infection control practices.
7,27-29
Pappas et al.
30 described the predominance of C.
parapsilosis fungemia in children, and they suggested
that the high prevalence of C. parapsilosis in
children may reflect the aggressive use of
intravascular devices to treat neonates. Shin et
al.
27 also reported that the increased incidence of
candidemia due to C. parapsilosis was mainly from
central venous catheter-related candidemia that
occurs in non-neutropenic patients receiving total
parenteral nutrition.
Pfaller et al.
21 reported variation in the rank
order and frequency of different Candida species
over time and by the geographic area. Our study
also showed variation in the rank order of
occurrence of various BSI-causing species of
Candida among different hospitals in Korea. Diffe-
rences in patient populations, underlying diseases,
antifungal therapies, and infection control prac-
tices, in addition to other hospital-specific factors,
may account for the variation.
2
Our data pertaining to fluconazole and itraco-
nazole MICs for four common Candida species (C.
albicans, C. parapsilosis, C. glabrata, and C. tropicalis)
were similar to those reported in countries partici-
pating in the SENTRY Antimicrobial Surveillance
Program.
5,25 The percent resistance to both fluco-
nazole and itraconazole of each Candida species
were also comparable to what was reported in the
SENTRY study
5,25 (p > 0.05).
Among the species of Candida associated with
BSI in this study, resistance to fluconazole and
itraconazole was largely limited to the isolates of
C. glabrata and C. krusei. The MIC50s of all three
azoles for C. glabrata were higher than those
observed for most of the other species. The C.
glabrata was the main causative agent of BSI in
only one of the eight hospitals. The elevated
frequency of C. glabrata-related BSI in this parti-
cular hospital is worth noting, because of the
propensity of this species to develop resistance
upon exposure to azole antifungals.
31 Therefore,Jin-Sol Lee, et al.
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fluconazole may not be the initial therapy of
choice for such infections until the susceptibility
test results are known, and it may not be an
appropriate choice at all in extremely ill patients.
32
In this study, none of the C. parapsilosis isolates
were azole-resistant; however, two isolates
showed decreased susceptibility to both fluco-
nazole (MIC range from 16 to 32 g/mL) and μ
itraconazole (MIC range from 0.25 to 0.5 g/mL). μ
The explanation for this is unknown at this time.
These findings highlight the need to study the
resistance mechanisms of these isolates and to
continue our study with a larger number of
Candida isolates.
Only a small proportion of the Candida isolates
tested in our study showed azole resistance.
Voriconazole was quite effective against all
Candida species tested, which is in agreement with
other reports.
33,34 The percentages of fluconazole-
and itraconazole-resistant organisms causing can-
didemia were low (2% and 4%, respectively).
None of the C. albicans, C. parapsilosis, or C.
tropicalis strains was resistant to triazoles. In
addition, 94% (15/16) of the C. glabrata isolates in
this study were inhibited by fluconazole at con-
centrations of 32 g/mL or less, and thus may still μ
respond to the recommended doses of this agent
( 400 mg/day).
35 These findings have important
implications for the management of Candida-
related BSI, especially given that fluconazole is
widely used for the treatment of uncomplicated
candidemia.
36 The negligible incidence of fluco-
nazole resistance among our Candida isolates
supports the current belief that antifungal
susceptibility testing should not be routinely
performed for such common Candida species such
as C. albicans, C. parapsilosis, and C. tropicalis;
however, it may be required for patients who fail
to respond to the initial therapy or who develop
breakthrough candidemia while receiving fluco-
nazole prophylaxis.
32
In summary, we have shown that the C. albicans
is the predominant species in Korean hospitals,
and that the azole-resistant BSI-related isolates of
Candida are still rare in Korea. These data suggest
that the azole antifungals, including fluconazole,
remain highly effective agents against most major
Candida isolates in Korea. However, we also found
variability in the frequency of C. glabrata as a
cause of BSI among different hospitals, and
decreased susceptibility of a few isolates of C.
parapsilosis to fluconazole. Therefore, continuous
national surveillance programs are needed in
order to identify possible changes in the species
distribution and antifungal susceptibility patterns
of Candida that may occur due to the increased use
of antifungal agents in Korea.
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